These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34070642)

  • 61. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.
    Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):53-61. PubMed ID: 31792640
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
    Digumarti R; Sinha S; Nirni SS; Patil SG; Pedapenki RM
    Indian J Cancer; 2014; 51(2):180-3. PubMed ID: 25104205
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Refractory gout: what is it and what to do about it?
    Fels E; Sundy JS
    Curr Opin Rheumatol; 2008 Mar; 20(2):198-202. PubMed ID: 18349751
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Therapeutic perspectives on uricases for gout.
    Garay RP; El-Gewely MR; Labaune JP; Richette P
    Joint Bone Spine; 2012 May; 79(3):237-42. PubMed ID: 22366146
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study.
    Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):44-52. PubMed ID: 31754882
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.
    Schumacher HR
    Expert Opin Investig Drugs; 2005 Jul; 14(7):893-903. PubMed ID: 16022578
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Natural products for the management of hyperuricaemia and gout: a review.
    El-Tantawy WH
    Arch Physiol Biochem; 2021 Feb; 127(1):61-72. PubMed ID: 31094218
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Gout and hyperuricemia.
    Chilappa CS; Aronow WS; Shapiro D; Sperber K; Patel U; Ash JY
    Compr Ther; 2010; 36():3-13. PubMed ID: 21229813
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
    Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
    Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
    Kuriyama S
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):1-5. PubMed ID: 31754883
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice.
    Liang G; Nie Y; Chang Y; Zeng S; Liang C; Zheng X; Xiao D; Zhan S; Zheng Q
    Phytomedicine; 2019 Jun; 59():152772. PubMed ID: 31005813
    [TBL] [Abstract][Full Text] [Related]  

  • 73. New developments in clinically relevant mechanisms and treatment of hyperuricemia.
    Lee SJ; Terkeltaub RA
    Curr Rheumatol Rep; 2006 Jun; 8(3):224-30. PubMed ID: 16901081
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study.
    Hosoya T; Sasaki T; Hashimoto H; Sakamoto R; Ohashi T
    J Clin Pharm Ther; 2016 Jun; 41(3):298-305. PubMed ID: 27079434
    [TBL] [Abstract][Full Text] [Related]  

  • 75. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
    Torres RJ; Puig JG
    Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Uricase production by a recombinant Hansenula polymorpha strain harboring Candida utilis uricase gene.
    Chen Z; Wang Z; He X; Guo X; Li W; Zhang B
    Appl Microbiol Biotechnol; 2008 Jun; 79(4):545-54. PubMed ID: 18437374
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The identification of an integral membrane, cytochrome c urate oxidase completes the catalytic repertoire of a therapeutic enzyme.
    Doniselli N; Monzeglio E; Dal Palù A; Merli A; Percudani R
    Sci Rep; 2015 Sep; 5():13798. PubMed ID: 26349049
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Gout].
    Tausche AK
    Internist (Berl); 2021 May; 62(5):513-525. PubMed ID: 33721041
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Hyperuricemia and gout].
    Gröbner W
    Dtsch Med Wochenschr; 2015 Oct; 140(21):1615-26. PubMed ID: 26488103
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Genetic factors associated with gout and hyperuricemia.
    Bleyer AJ; Hart TC
    Adv Chronic Kidney Dis; 2006 Apr; 13(2):124-30. PubMed ID: 16580613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.